FDA review: Long-acting asthma drugs pose serious risks

12/7/2008 | NYTimes.com · Reuters

The FDA should revoke clearance for asthma drugs known as long-acting beta agonists for children in light of clinical evidence linking them to a higher risk of asthma attacks and death, according to a review from the agency's drug-safety personnel. The FDA plans to gather a panel of outside experts this week to evaluate the safety of AstraZeneca's Symbicort, Novartis AG's Foradil and GlaxoSmithKline's Advair and Serevent.

View Full Article in:

NYTimes.com · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
Washington DC, DC